

Giuliano Tocci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2698902/publications.pdf>

Version: 2024-02-01

249
papers

5,060
citations

109321

35
h-index

128289

60
g-index

258
all docs

258
docs citations

258
times ranked

7146
citing authors

#	ARTICLE	IF	CITATIONS
1	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1501-1509.	1.8	9
2	Prevalence and clinical characteristics of isolated systolic hypertension in young: analysis of 24h ambulatory blood pressure monitoring database. <i>Journal of Human Hypertension</i> , 2022, 36, 40-50.	2.2	3
3	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. <i>Journal of Nephrology</i> , 2022, 35, 211-221.	2.0	34
4	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. <i>Journal of Human Hypertension</i> , 2022, 36, 976-982.	2.2	20
5	Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 1-14.	2.2	26
6	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 105-113.	2.2	3
7	Ventriculo-arterial coupling in the intensive cardiac care unit: A non-invasive prognostic parameter. <i>International Journal of Cardiology</i> , 2022, 348, 85-89.	1.7	8
8	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 91-102.	2.2	17
9	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1245-1252.	2.6	15
10	Current applications and limitations of European guidelines on blood pressure measurement: implications for clinical practice. <i>Internal and Emergency Medicine</i> , 2022, 17, 645-654.	2.0	4
11	Socioeconomic status as determinant of individual cardiovascular risk. <i>Atherosclerosis</i> , 2022, 346, 82-83.	0.8	4
12	The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study. <i>Journal of Hypertension</i> , 2022, 40, 704-711.	0.5	12
13	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 353-359.	2.2	9
14	Antihypertensive drugs and the risks of cancer: More fakes than facts. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1323-1326.	1.8	5
15	Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. <i>Medical Principles and Practice</i> , 2021, 30, 122-130.	2.4	48
16	Real-life appraisal on blood pressure targets achievement in adult outpatients at high cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 472-480.	2.6	1
17	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. <i>Clinical Research in Cardiology</i> , 2021, 110, 1073-1082.	3.3	31
18	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 255-262.	2.2	1

#	ARTICLE	IF	CITATIONS
19	A Plea for Smoking-Free Policies in COVID-19 Times: Cardiovascular Prevention as an Ally in Coronavirus Containment. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 325-326.	2.2	0
20	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. <i>Frontiers in Physiology</i> , 2021, 12, 652163.	2.8	14
21	Hypertension Management and Control in Italy: A Real-World Survey in Elderly Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 425-426.	2.2	2
22	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 713652.	2.4	18
23	Trehalose, a natural disaccharide, reduces stroke occurrence in the stroke-prone spontaneously hypertensive rat. <i>Pharmacological Research</i> , 2021, 173, 105875.	7.1	15
24	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 62-69.	0.5	49
25	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 333-340.	0.5	46
26	New approach to blood pressure control: Triple combination pill. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 72-77.	4.9	13
27	Are we really sure about the pycnogenol antihypertensive effect?. <i>Pharmacological Research</i> , 2020, 151, 104543.	7.1	0
28	Blood Pressure Targets Achievement According to 2018 ESC/ESH Guidelines in Three European Excellence Centers for Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 51-59.	2.2	15
29	Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. <i>Internal and Emergency Medicine</i> , 2020, 15, 373-379.	2.0	3
30	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. <i>Hypertension</i> , 2020, 75, 302-308.	2.7	177
31	White-coat and masked hypertension and coronary artery disease: are they related or not?. <i>Hypertension Research</i> , 2020, 43, 151-152.	2.7	0
32	Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. <i>Angiology</i> , 2020, 71, 217-225.	1.8	5
33	Hypertensive crisis management in the emergency room. <i>Journal of Hypertension</i> , 2020, 38, 33-34.	0.5	7
34	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. <i>Journal of Hypertension</i> , 2020, 38, 412-419.	0.5	70
35	Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension. <i>Cardiology</i> , 2020, 145, 599-600.	1.4	1
36	Blood Pressure Target Achievement Under Monotherapy: A Real-Life Appraisal. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 587-596.	2.2	8

#	ARTICLE	IF	CITATIONS
37	Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion. <i>European Journal of Integrative Medicine</i> , 2020, 37, 101164.	1.7	3
38	Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 373-377.	2.2	14
39	Epidemiological Impact and Clinical Consequences of Masked Hypertension: A Narrative Review. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 195-201.	2.2	2
40	Age and Multimorbidity Predict Death Among COVID-19 Patients. <i>Hypertension</i> , 2020, 76, 366-372.	2.7	330
41	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. <i>International Journal of Cardiology</i> , 2020, 316, 172-179.	1.7	15
42	High Resolution Signal Averaged Electrocardiography May Improve Diagnosis of Atrial Fibrillation and Reduce Stroke. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 265-266.	2.2	0
43	Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for) Tj ETQq1 1,0,784314 rgBT /Over	2.2	93
44	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 907-914.	2.6	27
45	An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 531-539.	1.8	17
46	Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. <i>Journal of Hypertension</i> , 2020, 38, 1005-1015.	0.5	8
47	Ambulatory blood pressure and arterial stiffness web-based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive) Tj ETQq1 1 0,784314 rgBT /Over	2.2	93
48	Predictive Role of High Blood Pressure for the Incidence of Metabolic Syndrome. <i>Cardiology</i> , 2019, 142, 232-234.	1.4	1
49	Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension. <i>Current Hypertension Reports</i> , 2019, 21, 85.	3.5	9
50	Conventional and new electrocardiographic criteria for hypertension-mediated cardiac organ damage: A narrative review. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1863-1871.	2.0	11
51	Arterial hypertension in cancer: The elephant in the room. <i>International Journal of Cardiology</i> , 2019, 281, 133-139.	1.7	48
52	Nutrients and Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-Based Consensus Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 9-25.	2.2	50
53	Nation-wide hypertension screening in Italy: data from May Measurements Month 2017 in Europe. <i>European Heart Journal Supplements</i> , 2019, 21, D66-D70.	0.1	16
54	Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?. <i>Internal and Emergency Medicine</i> , 2019, 14, 903-905.	2.0	1

#	ARTICLE	IF	CITATIONS
55	Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: Room for monotherapy?. <i>International Journal of Cardiology</i> , 2019, 291, 105-111.	1.7	3
56	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. <i>Atherosclerosis</i> , 2019, 285, 40-48.	0.8	39
57	Implications of Guidelines for Hypertension Management in Europe. <i>Circulation Research</i> , 2019, 124, 972-974.	4.5	14
58	Hypertension in the elderly: which are the blood pressure threshold values?. <i>European Heart Journal Supplements</i> , 2019, 21, B105-B106.	0.1	10
59	The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2019, 286, 127-133.	1.7	19
60	Immigration Emergency in Italy: The Impact of Socioeconomic Status on Blood Pressure Levels and Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 467-473.	2.2	3
61	SERUM URIC ACID, INDEPENDENTLY OF ARTERIAL HYPERTENSION, PREDICTS NON-FATAL INCIDENT CEREBROVASCULAR EVENTS IN AN ITALIAN LARGE COHORT OF MEN AND WOMEN. SEARCH FOR A CUT-OFF VALUE. <i>Journal of Hypertension</i> , 2019, 37, e221-e222.	0.5	1
62	AWARENESS OF MAJOR CARDIOVASCULAR RISK FACTORS AND ITS RELATIONSHIP WITH MARKERS OF VASCULAR AGING. <i>Journal of Hypertension</i> , 2019, 37, e97.	0.5	0
63	Reclassification of Hypertensive Outpatients According to New US Guidelines on High Blood Pressure. <i>American Journal of Hypertension</i> , 2019, 32, 77-87.	2.0	14
64	Highlights of ESC/ESH 2018 Guidelines on the Management of Hypertension: What Every Doctor Should Know. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 1-8.	2.2	22
65	Excess of dyslipidemia in low income countries: The case of Colombia in the PURE study. <i>International Journal of Cardiology</i> , 2019, 290, 152-153.	1.7	1
66	24-Hour ambulatory blood pressure levels and control in a large cohort of adult outpatients with different classes of obesity. <i>Journal of Human Hypertension</i> , 2019, 33, 298-307.	2.2	6
67	How to Improve Patients's™ Adherence to Antihypertensive Therapy: A Simple Solution for a Big Trouble. <i>American Journal of Hypertension</i> , 2019, 32, 141-142.	2.0	0
68	Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 1605-1618.	10.3	94
69	Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 967-975.	2.0	6
70	Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy. <i>Clinical Cardiology</i> , 2018, 41, 788-796.	1.8	9
71	Prevalence and clinical outcomes of white-coat and masked hypertension: Analysis of a large ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 297-305.	2.0	36
72	Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 197-202.	2.2	35

#	ARTICLE	IF	CITATIONS
73	How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 25-34.	2.2	11
74	Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 5-7.	2.2	0
75	Is early and fast blood pressure control important in hypertension management?. International Journal of Cardiology, 2018, 254, 328-332.	1.7	56
76	EFFECT OF RESVERATROL ON BLOOD PRESSURE. Journal of Hypertension, 2018, 36, e123.	0.5	2
77	Measuring Central or Peripheral Blood Pressure Levels? That is the Question in the Modern Clinical Practice of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 415-416.	2.2	1
78	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 327-341.	2.2	18
79	Search of multiple markers of organ damage for better cardiovascular risk stratification in hypertension: Role of SHATS syndrome in the clinical practice. International Journal of Cardiology, 2018, 263, 154-155.	1.7	1
80	Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 253-259.	2.2	8
81	Nocturnal blood pressure patterns and cardiovascular outcomes in patients with masked hypertension. Journal of Clinical Hypertension, 2018, 20, 1238-1246.	2.0	19
82	Use of Fixed-Dose Combinations in Hypertension and Cardiovascular Disease Prevention. Updates in Hypertension and Cardiovascular Protection, 2018, , 225-235.	0.1	0
83	Hypertension Across the Atlantic: A Sprint or a Marathon?. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 99-102.	2.2	6
84	Time Trend Analysis of Hypertension Prevalence, Awareness, Treatment and Control in Italy: Novel Insights from Recent National Surveys in the General Population. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 103-105.	2.2	1
85	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 313-329.	2.2	9
86	Favourable impact of statin use on diastolic blood pressure levels. Journal of Hypertension, 2017, 35, 2086-2094.	0.5	13
87	Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 243-253.	2.2	5
88	Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 255-263.	2.2	3
89	Cardiovascular risk and hypertension control in Italy. Data from the 2015 World Hypertension Day. International Journal of Cardiology, 2017, 243, 529-532.	1.7	17
90	Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 850-857.	2.6	12

#	ARTICLE	IF	CITATIONS
91	Educational Interventions May Promote Better Blood Pressure Control in Russia. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 351-352.	2.2	0
92	Increased arterial stiffness and haemorrhagic transformation in ischaemic stroke after thrombolysis: A new marker of risk for cerebrovascular events and complications. International Journal of Cardiology, 2017, 243, 471-472.	1.7	5
93	Adding markers of organ damage to risk score models improves cardiovascular risk assessment: Prospective analysis of a large cohort of adult outpatients. International Journal of Cardiology, 2017, 248, 342-348.	1.7	15
94	[OP.3C.01] COMPARISON BETWEEN EUROPEAN SYSTEMATIC CORONARY RISK EVALUATION AND ITALIAN CUORE ALGORITHMS IN ADULT OUTPATIENTS FOLLOWED BY GENERAL PRACTITIONERS AND SPECIALISED CENTRES. Journal of Hypertension, 2017, 35, e30.	0.5	0
95	[OP.6A.06] PREVALENCE AND CLINICAL CHARACTERISTICS OF TRUE MASKED HYPERTENSION COMPARED TO REVERSE AND ISOLATED NOCTURNAL MASKED HYPERTENSION. Journal of Hypertension, 2017, 35, e56.	0.5	0
96	[PP.01.17] ADDING HYPERTENSION-RELATED MARKERS OF ORGAN DAMAGE TO RISK SCORE MODELS IMPROVES CARDIOVASCULAR RISK ASSESSMENT. Journal of Hypertension, 2017, 35, e97.	0.5	0
97	[PP.04.18] COMPARISON AMONG DIFFERENT ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY. Journal of Hypertension, 2017, 35, e116.	0.5	0
98	[BP.03.03] CARDIOVASCULAR RISK AND HYPERTENSION CONTROL IN ITALY. DATA FROM THE 2015 WORLD HYPERTENSION DAY. Journal of Hypertension, 2017, 35, e176-e177.	0.5	1
99	Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 463-472.	2.2	14
100	Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. Clinical Hypertension, 2017, 23, 10.	2.0	5
101	Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. Journal of Human Hypertension, 2017, 31, 258-262.	2.2	62
102	Hypertension and social determinants in a cohort of migrants acceding an outpatient clinic in Rome. European Journal of Public Health, 2017, 27, .	0.3	0
103	Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. Expert Opinion on Drug Safety, 2016, 15, 55-61.	2.4	20
104	Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. Expert Opinion on Drug Safety, 2016, 15, 3-10.	2.4	15
105	Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2016, 15, 35-54.	2.4	62
106	Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2016, 15, 11-34.	2.4	235
107	Tpâ€Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. International Journal of Cardiology, 2016, 221, 881-885.	1.7	2
108	Prevalence and Control of Hypertension in Different Macro-Areas in Italy: Analysis of a Large Database by the General Practice. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 387-393.	2.2	17

#	ARTICLE	IF	CITATIONS
109	Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy. <i>Journal of Clinical Hypertension</i> , 2016, 18, 551-556.	2.0	45
110	New Opportunities for Monitoring Blood Pressure Control and Awareness in the Population: Insights from 12-Year Editions of the World Hypertension Day. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 333-335.	2.2	5
111	Hypertension in Patients with Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , 2016, 18, 127.	2.9	5
112	Exploring New Options for Cardiovascular Disease Prevention May Improve Patients' Quality of Life and Outcomes. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 259-260.	2.2	0
113	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. <i>American Journal of Hypertension</i> , 2016, 29, 509-518.	2.0	23
114	Patient with Essential Hypertension and Diastolic Dysfunction. <i>Practical Case Studies in Hypertension Management</i> , 2016, , 23-41.	0.0	0
115	Impact of Hypertension on Global Cardiovascular Risk Stratification: Analysis of a Large Cohort of Outpatient Population in Italy. <i>Clinical Cardiology</i> , 2015, 38, 39-47.	1.8	7
116	Synergic effects of renin and aldosterone on right ventricular function in hypertension. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 831-838.	1.5	5
117	Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. <i>Internal and Emergency Medicine</i> , 2015, 10, 943-954.	2.0	7
118	Combination Therapy for the Clinical Management of Hypertension. , 2015, , 887-902.		0
119	A Novel Electrocardiographic T _w Measurement (Tp _{Te} Interval) as a Predictor of Heart Abnormalities in Hypertension: A New Opportunity for First-Line Electrocardiographic Evaluation. <i>Journal of Clinical Hypertension</i> , 2015, 17, 441-449.	2.0	13
120	Use of Fixed Combination Therapies to Improve Blood Pressure Control in the Clinical Management of Hypertension: A Key Opportunity. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 427-428.	2.2	0
121	Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. <i>European Journal of Internal Medicine</i> , 2015, 26, 255-258.	2.2	35
122	Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey. <i>Journal of Human Hypertension</i> , 2015, 29, 409-416.	2.2	6
123	Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 381-388.	2.2	43
124	Angiotensin II Receptor Blocker Nephilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 241-246.	2.2	19
125	Managing hypertension after acute coronary syndrome. <i>Journal of Hypertension</i> , 2015, 33, 700-701.	0.5	0
126	Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 429-444.	2.2	61

#	ARTICLE	IF	CITATIONS
127	Metabolic approaches to antihypertensive treatment in diabetic patients. <i>Hypertension Research</i> , 2015, 38, 802-803.	2.7	0
128	Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000â€“2005 and 2005â€“2011 hypertension surveys. <i>Journal of Human Hypertension</i> , 2015, 29, 696-701.	2.2	47
129	Clinical management of patients with hypertension and high cardiovascular risk in specialised centers and in general practice. Analysis from an Italian Survey Questionnaire. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 866-874.	2.6	4
130	Calcium Channel Blockers and Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 121-130.	2.0	40
131	Pâ€Wave Duration in Lead aVR and the Risk of Atrial Fibrillation in Hypertension. <i>Annals of Noninvasive Electrocardiology</i> , 2015, 20, 167-174.	1.1	16
132	Understanding and treating hypertension in diabetic populations. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 353-63.	1.7	11
133	Prevalence of metabolic syndrome in the clinical practice of general medicine in Italy. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 271-9.	1.7	12
134	Revisiting the Relationship Between Blood Pressure and Insulin-Like Growth Factor-1. <i>Hypertension</i> , 2014, 63, 1070-1077.	2.7	45
135	Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?. <i>ISRN Cardiology</i> , 2014, 2014, 1-7.	1.6	7
136	Reducing therapeutic inertia to improve blood pressure control. <i>Journal of Hypertension</i> , 2014, 32, 988-989.	0.5	0
137	National Survey on Excellence Centers and Reference Centers for Hypertension Diagnosis and Treatment: Geographical Distribution, Medical Facilities and Diagnostic Opportunities. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 29-36.	2.2	7
138	Abnormal Regulation of Renin Angiotensin Aldosterone System Is Associated With Right Ventricular Dysfunction in Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 188-194.	1.7	18
139	Clinical Management of Patients with Hypertension and High Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 107-117.	2.2	12
140	An atypical clinical presentation of renovascular hypertension. <i>International Journal of Cardiology</i> , 2014, 177, e107-e110.	1.7	1
141	Hypertension in Premenopausal Women: Is There Any Difference?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 195-199.	2.2	8
142	Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. <i>Journal of Human Hypertension</i> , 2014, 28, 74-79.	2.2	192
143	2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 45-52.	2.2	57
144	Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. <i>Clinical Research in Cardiology</i> , 2013, 102, 725-733.	3.3	20

#	ARTICLE	IF	CITATIONS
145	Strategies to improve control of blood pressure in hypertension: moving towards a 70% objective. Expert Review of Cardiovascular Therapy, 2013, 11, 653-656.	1.5	1
146	New Oral Anticoagulants in Non-Valvular Atrial Fibrillation. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 53-60.	2.2	3
147	Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence. Drugs and Aging, 2013, 30, 987-998.	2.7	10
148	Synergic effect of high renin and aldosterone levels on inappropriate left ventricular mass and systolic function: A tissue Doppler study. International Journal of Cardiology, 2013, 168, 4934-4936.	1.7	4
149	Preclinical effects of healthy obesity on inappropriate left ventricular mass and systolic function. International Journal of Cardiology, 2013, 167, 3047-3049.	1.7	5
150	Renin-angiotensin system blockers increase risk of angio-oedema. Evidence-Based Medicine, 2013, 18, e52-e52.	0.6	0
151	Erythropoietin in cardiac disease. Journal of Cardiovascular Medicine, 2013, 14, 870-878.	1.5	17
152	Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. Hypertension Research, 2013, 36, 36-42.	2.7	28
153	Relation between right and left ventricular function in patients undergoing chronic dialysis. Journal of Cardiovascular Medicine, 2013, 14, 289-295.	1.5	20
154	Follow-up, study design and outcome parameters. EuroIntervention, 2013, 9, R96-R100.	3.2	1
155	Involvement of Health Professionals: From the General Practitioner to the Hypertension Specialist and the Hypertension Center. , 2013, , 181-191.		0
156	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation. Journal of Hypertension, 2012, 30, 1056-1064.	0.5	86
157	Blood pressure control in Italy. Journal of Hypertension, 2012, 30, 1065-1074.	0.5	78
158	Shooting beyond score. Journal of Hypertension, 2012, 30, 1909-1910.	0.5	1
159	Non-Invasive Diagnostic Testing for Coronary Artery Disease in the Hypertensive Patient: Potential Advantages of a Risk Estimation-Based Algorithm. American Journal of Hypertension, 2012, 25, 1226-35.	2.0	14
160	Renin as a biomarker of cardiovascular disease in clinical practice. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 312-317.	2.6	18
161	Pathophysiology of biventricular dysfunction during hemodialysis: Emerging concepts. International Journal of Cardiology, 2012, 155, 478-479.	1.7	9
162	The clinical relevance of dysfunctional HDL in patients with coronary artery disease: A 3-year follow-up study. International Journal of Cardiology, 2012, 158, 158-160.	1.7	7

#	ARTICLE	IF	CITATIONS
163	Renal Artery Denervation for Treating Resistant Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 237-244.	2.2	19
164	Global cardiovascular risk management in different Italian regions: An analysis of the evaluation of final feasible effect of control training and ultra sensitisation (EFFECTUS) educational program. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 635-642.	2.6	14
165	Triple combination therapy to improve blood pressure control: experience with olmesartan+amlodipine+hydrochlorothiazide therapy. Expert Opinion on Pharmacotherapy, 2012, 13, 2687-2697.	1.8	8
166	A Survey on Blood Pressure Levels and Hypertension Control in a Sample of the Italian General Population. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 129-135.	2.2	0
167	An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 73-83.	2.2	6
168	Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vascular Health and Risk Management, 2012, 8, 371.	2.3	18
169	Early cardiac abnormalities and increased C-reactive protein levels in a cohort of children with sleep disordered breathing. Sleep and Breathing, 2012, 16, 101-110.	1.7	36
170	Use of aliskiren in a "real-life" model of hypertension management. Journal of Hypertension, 2012, 30, 194-203.	0.5	19
171	A Survey on Blood Pressure Levels and Hypertension Control in a Sample of the Italian General Population. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 129-135.	2.2	14
172	Global Cardiovascular Risk Management in Primary Prevention. Current Vascular Pharmacology, 2012, 10, 709-711.	1.7	3
173	An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 73-83.	2.2	5
174	An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 19-30.	2.2	7
175	Prevalence of "Borderline" Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 43-51.	2.2	3
176	High Blood Pressure, Ventricular Tachycardia and Transient Left Ventricular Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 57-59.	2.2	2
177	Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy. Expert Review of Cardiovascular Therapy, 2011, 9, 829-840.	1.5	4
178	Modern Clinical Management of Arterial Hypertension. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 3-11.	2.2	7
179	End-Organ Protection in Patients with Hypertension. Drugs, 2011, 71, 1003-1017.	10.9	9
180	Impact of dialysis modality on the appropriateness of left ventricular mass in patients with end-stage renal disease. International Journal of Cardiology, 2011, 149, 250-252.	1.7	11

#	ARTICLE	IF	CITATIONS
181	Aortic root dilatation in hypertensive patients: A multicenter survey in echocardiographic practice. <i>Blood Pressure</i> , 2011, 20, 267-273.	1.5	23
182	Olmesartan medoxomil for the treatment of hypertension in children and adolescents. <i>Vascular Health and Risk Management</i> , 2011, 7, 177.	2.3	3
183	Fixed combination therapies based on direct renin inhibition: a commentary to the ACCELERATE trial. <i>Clinical Investigation</i> , 2011, 1, 605-610.	0.0	0
184	Impact of physicians' age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation Educational Programme. <i>International Journal of Clinical Practice</i> , 2011, 65, 649-657.	1.7	2
185	Impact of Diabetes Mellitus on the Clinical Management of Global Cardiovascular Risk: Analysis of the Results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) Educational Program. <i>Clinical Cardiology</i> , 2011, 34, 560-566.	1.8	11
186	Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. <i>Current Hypertension Reports</i> , 2011, 13, 318-324.	3.5	31
187	Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials. <i>American Journal of Hypertension</i> , 2011, 24, 1060-1068.	2.0	14
188	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials. <i>American Journal of Hypertension</i> , 2011, 24, 582-590.	2.0	78
189	Network Meta-analysis of Heart Failure Prevention by Antihypertensive Drugs"Reply. <i>Archives of Internal Medicine</i> , 2011, 171, 472.	3.8	0
190	Antihypertensive Treatment and Development of Heart Failure in Hypertension. <i>Archives of Internal Medicine</i> , 2011, 171, 384-94.	3.8	134
191	Prevalence and Correlates of Echocardiographic Left Atrial Enlargement in Hypertensive Outpatients in Clinical Practice. <i>Clinical and Experimental Hypertension</i> , 2011, 33, 328-335.	1.3	16
192	A Review of Angiotensin Receptor Blocker-based Therapies at all Levels of Cardiovascular Risk. <i>European Cardiology Review</i> , 2011, 7, 254.	2.2	1
193	Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. <i>Journal of Hypertension</i> , 2010, 28, 251-258.	0.5	25
194	Prediction of Long-Term Survival in Chronic Heart Failure by Multiple Biomarker Assessment: A 15-Year Prospective Follow-Up Study. <i>Clinical Cardiology</i> , 2010, 33, 700-707.	1.8	31
195	Rethinking targets of blood pressure and guidelines for hypertension clinical management. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3465-3471.	0.7	6
196	Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 811-820.	1.5	21
197	Echocardiography in clinical practice: the burden of arterial hypertension. A multicenter Italian survey. <i>Journal of Human Hypertension</i> , 2010, 24, 395-402.	2.2	13
198	Right Ventricular Dysfunction in Patients with End-Stage Renal Disease. <i>American Journal of Nephrology</i> , 2010, 32, 432-438.	3.1	75

#	ARTICLE	IF	CITATIONS
199	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 37-47.	2.2	13
200	Evaluation of Systolic Properties in Hypertensive Patients With Different Degrees of Diastolic Dysfunction and Normal Ejection Fraction. American Journal of Hypertension, 2009, 22, 437-443.	2.0	21
201	Management of hypertension and stroke prevention: results of the Italian cardiologist survey. International Journal of Clinical Practice, 2009, 63, 207-216.	1.7	20
202	Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Review of Cardiovascular Therapy, 2009, 7, 115-123.	1.5	13
203	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. Journal of Hypertension, 2009, 27, 941-946.	0.5	29
204	2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. Journal of Hypertension, 2009, 27, S3-S11.	0.5	31
205	Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clinical Science, 2009, 116, 467-477.	4.3	122
206	Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2009, 27, 410-417.	0.5	28
207	Global Cardiovascular Risk Assessment in Different Clinical Settings. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 55-63.	2.2	13
208	Managing hypertension in cardiology practice according to risk profile. International Journal of Clinical Practice, 2008, 62, 1403-1412.	1.7	14
209	1.10 Superiority of Apolipoproteins Compared to Non-HDL Cholesterol in Predicting the Presence of Coronary Disease in Hypertensive Patients with Ischemic Heart Disease. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 180-180.	2.2	0
210	1.11 Prevalence of Metabolic Alterations In Hypertensive Patients with Stable vs Unstable Angina. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 181-181.	2.2	0
211	Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines. Current Hypertension Reviews, 2008, 4, 234-240.	0.9	0
212	Development of heart failure in recent hypertension trials. Journal of Hypertension, 2008, 26, 1477-1486.	0.5	105
213	Use of predictive markers to improve cardiovascular protection. Future Cardiology, 2007, 3, 447-456.	1.2	2
214	Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy, 2007, 5, 767-776.	1.5	14
215	Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension. Current Hypertension Reviews, 2007, 3, 196-202.	0.9	0
216	Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. Journal of Hypertension, 2007, 25, 833-839.	0.5	35

#	ARTICLE	IF	CITATIONS
217	Blood pressure control in Italy: results of recent surveys on hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1491-1498.	0.5	117
218	Markers of Inflammation and Fibrosis Are Related to Cardiovascular Damage in Hypertensive Patients with Metabolic Syndrome. <i>American Journal of Hypertension</i> , 2007, 20, 784-791.	2.0	93
219	Justificación de la terapia combinada con IECA y bloqueadores de los canales de calcio en la hipertensión. <i>Hipertension</i> , 2007, 24, 256-260.	0.0	0
220	Angiotensin II Receptor Antagonists. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 39-47.	2.2	0
221	Upcoming Challenges for Training in Cardiology. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 201-206.	2.2	1
222	Chronic AC-SDKP Administration Reduces Cardiac and Renal Perivascular Fibrosis in Diabetic Rats. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 145-196.	2.2	0
223	Conventional and Tissue Doppler Evaluation of Systolic and Diastolic Function in a Cohort of Paediatric Obese Subjects. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 145-196.	2.2	0
224	Impact of Diabetes and Impaired Glucose Tolerance (IGT) on Complications and Hospitalisation in Patients with Acute Coronary Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 145-196.	2.2	0
225	Central Adiposity, Blood Pressure Variability and Endothelial Activation in Light-to-Moderate Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 145-196.	2.2	1
226	Multivariate risk assessment and risk score cards in hypertension. <i>Vascular Health and Risk Management</i> , 2007, 3, 313-20.	2.3	4
227	Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. <i>Journal of Nephrology</i> , 2007, 20 Suppl 12, S12-8.	2.0	3
228	Treatment of High-Risk Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006, 13, 13-19.	2.2	0
229	Antihypertensive therapy and cerebrovascular protection. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 498-504.	2.0	9
230	Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S36-S43.	6.1	35
231	Tumor necrosis factor- α as trigger of platelet activation in patients with heart failure. <i>Blood</i> , 2005, 106, 1992-1994.	1.4	94
232	Angiotensin II-receptor antagonist in the treatment of hypertension. <i>Current Hypertension Reports</i> , 2005, 7, 287-293.	3.5	7
233	Angiotensin II receptor blockers and coronary artery disease: 'presumed innocents'. <i>European Heart Journal</i> , 2005, 27, 1506-1507.	2.2	4
234	Adverse Effects of Statins. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 141-148.	2.2	1

#	ARTICLE	IF	CITATIONS
235	How to Manage Metabolic Syndrome. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 231-238.	2.2	2
236	Integrated cardiovascular risk management for the future: lessons learned from the ASCOT trial. Aging Clinical and Experimental Research, 2005, 17, 46-53.	2.9	12
237	Hypertension and Heart Failure: Role of Neurohormonal Mechanisms. Clinical and Experimental Hypertension, 2004, 26, 603-610.	1.3	8
238	Protocol for an Observational Blood Pressure Study. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 11-14.	2.2	3
239	Cardiovascular Risk Profile in 1477513 Patients with Essential Hypertension Followed by Italian Specialist Physicians. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 165-173.	2.2	6
240	The REassessment of Antihypertensive Chronic Therapy (REACT) Study. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 175-185.	2.2	16
241	410 Altered TCR-mediated signalling in T cells from HCV-chronically infected patients. Journal of Hepatology, 2004, 40, 122.	3.7	0
242	Biological relevance of a proANP molecular variant in human endothelial cells. American Journal of Hypertension, 2003, 16, A67.	2.0	0
243	Oxidative Stress and Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 27-33.	2.2	0
244	Long-Term Tolerability and Efficacy of the Fixed Combination of Manidipine and Delapril in Patients with Essential Hypertension. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 81-86.	2.2	7
245	Enhanced TNF α and oxidative stress in patients with heart failure: effect of TNF α on platelet O ₂ - production. Thrombosis and Haemostasis, 2003, 90, 317-325.	3.4	58
246	Imipenem-cilastatin for the treatment of bacterial complications in the immunocompromised host. Current Therapeutic Research, 1992, 52, 753-756.	1.2	0
247	Spontaneous remission of hepatocellular carcinoma after massive gastrointestinal haemorrhage.. BMJ: British Medical Journal, 1990, 300, 641-642.	2.3	55
248	PLASMAPHERESIS FOR LATE-STAGE TRYPANOSOMIASIS. Lancet, The, 1989, 333, 1200.	13.7	4
249	Diastolic Blood Pressure Levels and Cardiovascular Risk in Elderly Women: The Need for a Personalized Approach. American Journal of Hypertension, 0, , .	2.0	0